Not all weight loss on GLP-1 medications is healthy weight loss
A seasoned cardiologist's warning about GLP-1 weight-loss drugs invites us to reckon with a familiar human tendency: mistaking the appearance of progress for progress itself. Dr. Sanjay Bhojraj, drawing on over two decades of clinical practice, cautions that medications like Ozempic may quietly erode the very muscle tissue that sustains long-term metabolic health, leaving patients lighter on the scale but biologically more fragile. The concern is not with the drugs themselves, but with the illusion of transformation they can produce when used without the discipline of diet, exercise, and a thoughtful plan for what comes after.
- Millions are turning to GLP-1 drugs for rapid weight loss, but a prominent cardiologist warns the scale may be hiding a dangerous trade: fat lost alongside muscle that the body cannot easily rebuild.
- When appetite is suppressed and protein intake falls, the body cannibalizes lean muscle tissue — a process called sarcopenia — quietly undermining the metabolic engine patients are trying to repair.
- The moment patients stop the medication, studies show weight surges back, often with worsened blood sugar, blood pressure, and cholesterol, because the body was suppressed rather than retrained.
- Beyond muscle loss, the FDA has repeatedly updated safety warnings to include gastroparesis, kidney injury, gallbladder disease, and a surgical aspiration risk tied to delayed stomach emptying.
- Medical experts are now calling for a structured framework around GLP-1 use — high protein intake, resistance training, and a deliberate exit strategy — to prevent patients from ending up metabolically worse than when they started.
Dr. Sanjay Bhojraj, an interventional cardiologist with more than twenty years of US practice, issued a pointed warning on Instagram in mid-June: not all the weight disappearing on GLP-1 medications like Ozempic is fat. A significant portion, he cautioned, may be muscle — and that distinction carries consequences the scale cannot reveal.
The mechanism is straightforward. These drugs suppress appetite, reducing caloric intake sharply. When the body burns through its energy reserves, it does not discriminate neatly between fat and lean tissue. The resulting muscle loss, known as sarcopenia, depresses the resting metabolic rate — meaning the body becomes less efficient at burning energy precisely when patients are most vulnerable, particularly after stopping the medication.
Bhojraj described this as a trap disguised as success. Patients who skip adequate protein, avoid resistance training, and ignore digestive health may be trading fat for muscle — an exchange that flatters the scale while leaving the body weaker. Research supports his concern: when GLP-1 therapy ends, lost weight frequently returns alongside worsening blood sugar, blood pressure, and cholesterol, because the body was suppressed rather than genuinely retrained.
The risks extend further. Active lawsuits cite serious gastrointestinal injuries including gastroparesis and intestinal obstruction. The FDA has updated its safety labels to warn of gallbladder disease, acute kidney injury, severe constipation, and a surgical hazard — because delayed gastric emptying means patients may retain stomach contents even after pre-operative fasting, raising aspiration risks under anesthesia.
Bhojraj is not calling for abandonment of these medications, but for a comprehensive framework around their use: aggressive protein intake, heavy resistance training, close clinical supervision, and a concrete exit plan. The broader medical conversation is shifting accordingly — from 'take this and lose weight' to 'take this as part of a deliberate, supervised strategy.' The scale, he reminds us, tells only part of the story.
Dr. Sanjay Bhojraj, an interventional cardiologist with more than twenty years of practice in the United States, posted a warning on Instagram in mid-June that cut against the prevailing enthusiasm surrounding GLP-1 receptor agonists. The drugs—Ozempic, Wegovy, and experimental compounds like retatrutide—have become synonymous with rapid weight loss. But Bhojraj's message was direct: not all the weight that comes off is fat. Much of it, he cautioned, could be muscle.
The mechanism is straightforward enough. These medications work by suppressing appetite, which means patients eat less. When caloric intake drops sharply, the body burns through its energy reserves. The problem emerges when those reserves include lean muscle tissue alongside fat. This process, called sarcopenia in medical terms, carries consequences that extend far beyond the scale. Muscle is metabolically active—it burns calories even at rest. Lose enough of it, and your resting metabolic rate plummets. The body becomes less efficient at burning energy, a vulnerability that becomes acute the moment a patient stops taking the medication.
Bhojraj framed the issue as a trap disguised as success. Patients see the numbers drop and assume they are getting healthier. But if they are barely eating protein, not lifting weights, and ignoring the mechanics of digestion, they are likely trading fat for muscle—a trade that looks good on a scale but leaves the body weaker and more prone to regaining weight. "Not all weight loss on GLP-1 medications is healthy weight loss," he said. The distinction matters because it separates genuine metabolic improvement from the illusion of it.
The rebound effect is well-documented in the research. When patients discontinue GLP-1 therapy, studies show that much of the lost weight returns, often accompanied by worsening markers: higher blood sugar, elevated blood pressure, worse cholesterol profiles. The body has not been retrained to maintain a healthier state. It has simply been suppressed, and once the suppression lifts, it reverts to its previous patterns—or worse.
Beyond the muscle-loss concern, Bhojraj pointed to a growing legal and regulatory landscape that reveals additional risks. Active lawsuits allege serious gastrointestinal injuries, including gastroparesis—a condition where the stomach empties too slowly—and intestinal obstruction. The FDA has updated its safety labels repeatedly to reflect real-world data, adding warnings about gallbladder disease, acute kidney injury, severe constipation, and a particularly concerning risk during surgery: pulmonary aspiration. Because GLP-1s delay gastric emptying, patients may still have food in their stomachs even after fasting before anesthesia, creating a hazard for surgical teams.
Bhojraj emphasized that he is not opposed to GLP-1 medications outright. Rather, he views them as tools that require a comprehensive framework to work safely and effectively. That framework includes aggressive protein intake to preserve muscle, heavy resistance training to signal the body to retain lean mass, and close collaboration with clinical teams to develop an exit strategy—a plan for maintaining weight loss after medication stops. Without these elements, the drugs become a temporary fix that leaves patients metabolically worse off than before.
Medical guidelines are beginning to reflect this more cautious, structured approach. The conversation around GLP-1s is shifting from "take this pill and lose weight" to "take this pill as part of a deliberate, supervised plan that includes diet, exercise, and a realistic path forward." For patients considering these medications, the message is clear: the scale tells only part of the story. What matters is what you are actually losing, and whether you have a plan to keep it off.
Notable Quotes
People confuse eating less with getting healthier, and the biggest mistake is losing weight while barely eating protein, not strength training, and never building the habits that keep the weight off later.— Dr. Sanjay Bhojraj
You need a game plan when it comes to these medications—they must be viewed as tools within a broader metabolic framework rather than standalone cures.— Dr. Sanjay Bhojraj
The Hearth Conversation Another angle on the story
Why does muscle loss matter so much if the weight is still coming off?
Because muscle is what keeps your metabolism running. Lose it, and your body burns fewer calories even when you're sitting still. Once you stop the medication, you're left with a slower engine and the same appetite triggers you had before.
So the weight comes back?
Often it does, and sometimes worse. The studies show that when people stop GLP-1s, they regain weight along with worse blood sugar, blood pressure, and cholesterol. The body hasn't learned anything new—it's just been held in place.
What would actually work, then?
You need protein, strength training, and a real plan for life after the medication. The drug is a tool, not a solution. Without those other pieces, you're just borrowing time.
Is the doctor saying people shouldn't use these drugs at all?
No. He's saying use them intelligently, with supervision and a complete strategy. The danger is treating them as standalone fixes. They're not.
What about the side effects he mentioned—the surgery risks?
That's the regulatory reality catching up with real-world use. Delayed stomach emptying means food stays in your system longer, which creates hazards during anesthesia. It's a concrete medical problem that surgical teams now have to account for.
So what's the takeaway for someone considering this?
Ask yourself: Am I willing to commit to protein, resistance training, and a long-term plan? If not, this drug will likely disappoint you in the end.